EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Noninvasive Evaluation of Trop2 Expression Using 64 Cu-NOTA-Trodelvy-F(ab’) 2 in Gastric and Pancreatic Cancer

Wenpeng Huang, Fangfang Chao, Ruobing Li, Yihan Yang, Jessica C Hsu, Molly C DeLuca, Jonathan W Engle iD, Xingmin Han, Lei Kang iD, Weibo Cai iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c01223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Wenpeng Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Pancreatic Neoplasms, Antigens, Neoplasm, Cell Adhesion Molecules. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to develop and evaluate a 64Cu-labeled NOTA-conjugated F(ab')2 fragment of Trodelvy for ImmunoPET imaging of Trop2 expression in gastric and pancreatic cancer models. Trodelvy was enzymatically digested using IdeS protease to generate F(ab')2 fragments, which were subsequently conjugated to a NOTA chelator and radiolabeled with 64Cu. In vitro binding affinity and cellular uptake were assessed in Trop2-positive and Trop2-negative cancer cell lines using flow cytometry, immunofluorescence, and cell binding assays. In vivo ImmunoPET imaging and biodistribution studies were conducted in subcutaneous xenograft models. In NCI-N87 xenografts, 64Cu-NOTA-Trodelvy-F(ab')2 showed peak tumor uptake at 12 h postinjection (10.83 ± 2.76%ID/g), significantly higher than in HGC-27 (3.33 ± 1.12%ID/g, p = 0.0110). In BxPC3 xenografts, uptake reached 10.00 ± 0.89%ID/g at 12 h, compared to 3.13 ± 0.96%ID/g in AsPC1 (p < 0.0001). Tumor-to-heart ratios were significantly improved in Trop2-positive tumors: NCI-N87 (3.53 ± 0.22 vs 0.83 ± 0.34 for intact Trodelvy, p = 0.0003) and BxPC3 (3.77 ± 0.07 vs 0.77 ± 0.19, p < 0.0001). Ex vivo biodistribution at 48 h confirmed high tumor retention (NCI-N87: 4.14 ± 0.44%ID/g; BxPC3: 4.10 ± 0.31%ID/g) and significantly lower uptake in control and IgG-F(ab')2 groups (p < 0.01). Although renal uptake was elevated due to the clearance of antibody fragments, histological analyses showed no signs of off-target toxicity. The rapid tumor targeting and favorable pharmacokinetics of 64Cu-NOTA-Trodelvy-F(ab')2 support its utility as a same-day ImmunoPET imaging agent. This practical and sensitive platform is highly valuable for patient stratification and therapeutic monitoring in Trop2-targeted cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsPancreatic NeoplasmsAntigens, NeoplasmCell Adhesion MoleculesCopper RadioisotopesHeterocyclic Compounds, 1-RingImmunoglobulin Fab FragmentsHumansAnimalsMiceCell Line, TumorTissue DistributionPositron-Emission TomographyFemaleMice, NudeXenograft Model Antitumor AssaysMice, Inbred BALB CHeterocyclic Compounds

Stichwörter der Autor:innen

F(ab’)2 fragmentsTrop2gastric cancerimmunoPETpancreatic cancer

Substanzen

Antigens, NeoplasmTACSTD2 protein, humanCell Adhesion MoleculesCopper RadioisotopesHeterocyclic Compounds, 1-RingImmunoglobulin Fab Fragments1,4,7-triazacyclononane-N,N',N''-triacetic acidHeterocyclic Compounds

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
  • Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, Wisconsin 53705, United States.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province 450052, China.
  • College of Letters and Science, University of Wisconsin - Madison, Madison, Wisconsin 53705, United States.

ORCID-Profile: Jonathan W Engle, Lei Kang, Weibo Cai

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • National Natural Science Foundation of China

Zitieren

APA

Huang, W., Chao, F., Li, R., Yang, Y., Hsu, J. C., DeLuca, M. C., Engle, J. W., Han, X., Kang, L., & Cai, W. (2025). Noninvasive Evaluation of Trop2 Expression Using 64 Cu-NOTA-Trodelvy-F(ab’) 2 in Gastric and Pancreatic Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01223

Vancouver

Huang W, Chao F, Li R, Yang Y, Hsu JC, DeLuca MC, et al. Noninvasive Evaluation of Trop2 Expression Using 64 Cu-NOTA-Trodelvy-F(ab’) 2 in Gastric and Pancreatic Cancer. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c01223

BibTeX
@article{Huang2025,
  author = {Huang, Wenpeng and Chao, Fangfang and Li, Ruobing and Yang, Yihan and Hsu, Jessica C and DeLuca, Molly C and Engle, Jonathan W and Han, Xingmin and Kang, Lei and Cai, Weibo},
  title = {Noninvasive Evaluation of Trop2 Expression Using 64 Cu-NOTA-Trodelvy-F(ab’) 2 in Gastric and Pancreatic Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c01223}
}
Kostenlos starten →